TD Asset Management Inc Has $17.21 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR

TD Asset Management Inc increased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 5.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 221,178 shares of the company’s stock after buying an additional 11,930 shares during the period. TD Asset Management Inc owned 0.31% of Kymera Therapeutics worth $17,210,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the period. Bessemer Group Inc. grew its stake in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares during the period. Osaic Holdings Inc. lifted its position in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares in the last quarter. Raymond James Financial Inc. bought a new position in Kymera Therapeutics in the 2nd quarter valued at about $73,000. Finally, US Bancorp DE lifted its position in Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after acquiring an additional 166 shares in the last quarter.

Insider Activity

In other Kymera Therapeutics news, Director Bruce Booth sold 5,900 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00. Following the transaction, the director owned 5,641 shares of the company’s stock, valued at $507,464.36. This trade represents a 51.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jeremy G. Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at approximately $4,737,646.82. This represents a 59.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 260,115 shares of company stock worth $21,218,138. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Down 0.2%

Kymera Therapeutics stock opened at $73.95 on Tuesday. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $103.00. The company’s 50 day moving average price is $82.88 and its two-hundred day moving average price is $79.87. The stock has a market cap of $6.08 billion, a P/E ratio of -20.71 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter last year, the firm earned ($0.82) EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on KYMR. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Piper Sandler raised their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research report on Monday. BTIG Research dropped their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.